All In Biotech

Drug Trial Radar · NCT00833300

Haloperidol vs Olanzapine for the Management of ICU Delirium

Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Aug 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 2008

Primary completion

Nov 2011

Study completion Nov 2011

Sponsor

Lead sponsor
Richard HallAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dalhousie University
First posted
Feb 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized clinical trial is to determine whether haloperidol is superior to olanzapine for the treatment of ICU acquired delirium. The hypothesis is that haloperidol is in fact superior to olanzapine in treating ICU acquired delirium and sustaining delirium free time.

Conditions

  • Delirium
  • Agitation

Interventions

  • HaloperidolDrug

    * 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Discontinue current drug therapy and select one of: 1. Quetiapine up to 100 mg/day 2. Risperidone up to 6 mg/day 3. Loxapine up to 50 mg/day 4. Methotrimeprazine up to 75 mg/day * Reassess in 24 hours. * Delirium absent - Continue for 24 hours then discontinue. * Delirium present - Treatment at discretion of attending physician.

  • OlanzapineDrug

    * 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Discontinue current drug therapy and select one of: 1. Quetiapine up to 100 mg/day 2. Risperidone up to 6 mg/day 3. Loxapine up to 50 mg/day 4. Methotrimeprazine up to 75 mg/day * Reassess in 24 hours. * Delirium absent - Continue for 24 hours then discontinue. * Delirium present - Treatment at discretion of attending physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resolution of delirium as indicated by an Intensive Care Delirium Screening Checklist score of less than 4Time frame: Every 24 hours

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Halifax Infirmary; Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Victoria General Hospital; Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.